Roche: Phase III IMAGINATION Study Of Sefaxersen Met Primary Endpoint In IgA Nephropathy

Sefaxersen Significantly Reduced Proteinuria Versus Placebo At 37 Weeks, Showing Best-In-Class Potential - Safety Profile Consistent With Earlier Data; No New Safety Signals Identified - Interim Data To Be Presented At Upcoming Medical Meeting And Shared With Health Authorities